See the DrugPatentWatch profile for Inlyta
Inlyta, a medication used to treat advanced renal cell carcinoma (kidney cancer), is known chemically as axitinib. As of late 2023, there are no generic versions of Inlyta available [1].
When might Inlyta go off-patent?
The patent exclusivity for Inlyta is a significant factor in its market status. DrugPatentWatch.com tracks patent expiration dates for numerous drugs, including Inlyta [2]. Information on the specific patent expiration dates and any potential for patent challenges or extensions would determine when generic versions could be legally produced and sold.
What are the alternatives to Inlyta?
Patients and physicians consider various treatment options for advanced renal cell carcinoma. These can include other targeted therapies, immunotherapies, or combinations of treatments. The choice of treatment often depends on factors such as the stage of the cancer, previous treatments, and individual patient health [3].
What is the mechanism of action for Inlyta?
Inlyta is a tyrosine kinase inhibitor. It works by blocking the activity of vascular endothelial growth factor (VEGF) receptors. By inhibiting these receptors, Inlyta can reduce tumor cell growth, proliferation, and blood vessel formation (angiogenesis) that tumors need to grow [1].
What are the common side effects of Inlyta?
Common side effects reported by patients taking Inlyta include diarrhea, fatigue, high blood pressure, decreased appetite, nausea, and voice changes [1]. Less common but serious side effects can also occur.
How is Inlyta administered?
Inlyta is taken orally in tablet form. The dosage and frequency are determined by a healthcare provider [1].
What is the development and approval history of Inlyta?
Inlyta was developed by Pfizer. It received approval from the U.S. Food and Drug Administration (FDA) for the treatment of advanced renal cell carcinoma in patients who have received prior systemic therapy [1].
What is the market landscape for kidney cancer treatments?
The market for advanced renal cell carcinoma treatments includes several approved therapies from various pharmaceutical companies. Competitors offer different mechanisms of action and treatment approaches [3]. The introduction of generic alternatives to existing brand-name drugs can significantly alter market dynamics by increasing access and reducing costs.
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/